Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
Inventors
Baloglu, Erkan • Shacham, Sharon • Senapedis, William • McCauley, Dilara • Landesman, Yosef • Golan, Gali • Kalid, Ori • Shechter, Sharon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.
Core Innovation
The disclosed subject matter relates to compounds represented by Structural Formula IX, structural formulas recited in claims 13 and 20, and pharmaceutically acceptable salts thereof. The aminopyridinyl acrylamide compounds are built around benzofuran, benzoxazole, and related fused heteroaromatic cores such as furo[2,3-b]pyridine scaffolds. The compounds are defined by specified choices for variables m″, R1a, Z5, R20, R11, R12, R13, R21, and q, with disclosed embodiments encompassing Structural Formulas X–XII and substitutions including aryl, heteroaryl, cyclic amine, sulfonamide, and halogenated groups.
The disclosed compounds modulate PAK enzymes through mechanisms including PAK4 binding, allosteric effects, and target destabilization. Compound 585 demonstrates submicromolar antiproliferative activity across cancer cell lines while exhibiting limited activity in normal-cell assays, with PAK4 signaling reported to be largely unaffected in normal cells. Multiple compounds inhibit tumor growth in xenograft models, supporting the treatment of cancer and other PAK-mediated disorders. Reported evaluation includes an MTT cell proliferation assay in MS751 and Z138 cancer cells and 3T3 fibroblasts; [procedural detail omitted for safety].
Claims Coverage
The claims identify three independent claims, presenting three core inventive features directed to formula-defined compound classes and their pharmaceutically acceptable salts.
Compound represented by structural formula IX
Claim 1 covers a compound represented by Structural Formula IX, or a pharmaceutically acceptable salt thereof, defining selections for variables m″, R1a, Z5, R20, R11, R12, R13, R21, and q, including specified halogen, alkyl, haloalkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, carbonyl, thiocarbonyl, and sulfonyl groups.
Compound represented by structural formulas recited in claim 13
Claim 13 covers a compound represented by any one of the structural formulas recited in claim 13, or a pharmaceutically acceptable salt thereof.
Compound represented by structural formulas recited in claim 20
Claim 20 covers a compound represented by any one of the structural formulas recited in claim 20, or a pharmaceutically acceptable salt thereof.
The three independent claims define compound genera represented by Structural Formula IX or discrete structural formulas recited in claims 13 and 20, and pharmaceutically acceptable salts thereof, with dependent claims extending to pharmaceutical compositions and methods of treating cancer or other PAK-mediated disorders.
Stated Advantages
Compound 585 shows submicromolar antiproliferative activity across many cancer cell lines, with limited activity in several normal-cell assays.
Tumor growth inhibition is reported for the disclosed compounds in Z-138, Hep3B, MDA-MB-468, and MOLT-4 xenografts.
PAK4 signaling in normal cells is reported to be largely unaffected.
Documented Applications
Pharmaceutical compositions comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Methods of treating cancer by administering a therapeutically effective amount of a compound of claim 1, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the compound.
Methods of treating PAK-mediated disorders, including cancer, neurodegenerative disease, or immune system disease, using a compound of claim 1 or a pharmaceutically acceptable salt thereof.
Evaluation of compounds in an MTT cell proliferation assay involving MS751 and Z138 cancer cells and 3T3 fibroblasts; [procedural detail omitted for safety].
Interested in licensing this patent?